The estimated Net Worth of Miriam Provost is at least $3.96 Milione dollars as of 13 December 2023. Miriam Provost owns over 5,644 units of TransMedics stock worth over $3,960,527 and over the last 5 years he sold TMDX stock worth over $0. In addition, he makes $0 as Vice President - Global Regulatory Affairs at TransMedics.
Miriam has made over 8 trades of the TransMedics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 5,644 units of TMDX stock worth $252,908 on 13 December 2023.
The largest trade he's ever made was exercising 7,726 units of TransMedics stock on 2 September 2022 worth over $179,861. On average, Miriam trades about 2,929 units every 84 days since 2019. As of 13 December 2023 he still owns at least 27,540 units of TransMedics stock.
You can see the complete history of Miriam Provost stock trades at the bottom of the page.
Dr. Miriam Provost serves as Vice President - Global Regulatory Affairs of the Company. previously served as our Vice President of U.S. Regulatory and FDA Relations since February 2018, after serving as a key regulatory consulting advisor for us for over three years. Dr. Provost has over 23 years of experience in medical device regulatory affairs. Prior to joining TransMedics, Dr. Provost was an internationally recognized expert in FDA Regulatory Affairs and provided strategic guidance and tactical support for large and small medical device companies as a Senior Regulatory Consultant at the Biologics Consulting Group, Inc. Her expertise stems from 13 years as a reviewer and manager at the FDA where she served in a variety of roles across the agency, gaining broad knowledge and familiarity with all matters related to FDA policies, procedures and decision making.
Miriam Provost is 59, he's been the Vice President - Global Regulatory Affairs of TransMedics since 2019. There are 4 older and 12 younger executives at TransMedics. The oldest executive at TransMedics Group, Inc. is James Tobin, 75, who is the Independent Chairman of the Board.
Miriam's mailing address filed with the SEC is C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, ANDOVER, MA, 01810.
Over the last 5 years, insiders at TransMedics have traded over $99,976,312 worth of TransMedics stock and bought 154,333 units worth $3,250,328 . The most active insiders traders include Edwin M Jr Kania, Waleed H Hassanein e James R Tobin. On average, TransMedics executives and independent directors trade stock every 10 days with the average trade being worth of $2,982,476. The most recent stock trade was executed by Tamer I Khayal on 3 September 2024, trading 2,960 units of TMDX stock currently worth $98,065.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
TransMedics executives and other stock owners filed with the SEC include: